Background
==========

*Streptococcus agalactiae*(Group B *Streptococcus*\[GBS\]) was first identified as a significant public health concern in maternal fetal medicine in the 1970s. Since this time, more than 7500 cases of GBS-associated neonatal sepsis and meningitis have been reported annually, with a financial burden of more than \$350 million per year in neonatal costs \[[@B1]\]. Population-specific surveillance studies provide an important vehicle for evaluating the public health risks posed by changes in distribution of GBS serotypes \[[@B2]\].

Anogenital colonization with GBS is usually asymptomatic in immunocompetent adults \[[@B3]\]. Perinatal transmission of GBS from infected mothers during delivery can cause potentially fatal sepsis and meningitis \[[@B4]\]. Classification of GBS serotype is based on 10 immunologically unique capsular polysaccharides associated with pathogen virulence and encoded in the capsular gene cluster (*cps*) (Ia, Ib, II-IX) \[[@B5]\]. In the United States civilian population the predominant GBS serotypes are Ia, III, Ib, and V. Current multivalent vaccine development depends on accurate population data of serotype distribution \[[@B6]\]. Thus, epidemiological studies of seroprevalence are important in assessing changes in GBS distribution.

Accurate epidemiological characterization of GBS isolates is dependent on unequivocal classification of serotypes. Molecular methods have improved the accuracy and feasibility of serotyping, but these methods have only recently been applied to large cohorts \[[@B7]\].

Global serotyping distribution studies have documented that the prevalence of a given GBS serotype varies according to geographical location and time of study conductance \[[@B2]\]. Surveillance data in the United States come largely from civilian hospitals, with the Active Bacterial Core surveillance system within the Emerging Infections Program Network providing a mechanism for routine population-based surveillance \[[@B8]\]. Military communities are unique in their demographically diverse population including transients from military bases across the United States and around the world. It is unknown how the geographical mobility of the military might affect GBS seroprevalences in military cohorts.

Madigan Healthcare System (Madigan) is a tertiary care military medical center providing obstetric care to military families, with more than 2100 deliveries reported in 2009. Women between the ages of 18-40 are screened for GBS by urine cultures and vaginal/rectal swabs as standard of care. The objective of this study was to apply a two-tiered polymerase chain reaction (PCR) approach to determine the prevalence and distribution of the GBS serotypes in the Madigan population during the period covering July - December 2009 and to compare Madigan seroprevalences with global distributions.

Methods
=======

Study population
----------------

This study was performed with the approval of the Madigan Healthcare System Institutional Review Board. Of the 1129 patients screened during the study period (July 2009 - December 2009), 207 were scored as GBS positive (18.3%). Clinical GBS isolates from these patients were obtained from vaginal/rectal swabs routinely conducted on women of indeterminate gravidity between ages 18-40. GBS isolates were disassociated from any personal health information and assigned a unique study number correlating with the date of specimen collection.

Bacterial culture and banking
-----------------------------

GBS isolates were cultured from vaginal/rectal swabs. GBS positive diagnoses were confirmed by conventional morphologic and phenotypic methods. Isolated GBS colonies were obtained taking vaginal/rectal swabs and placing them directly into 5 ml of Lim enrichment broth (Fisher Scientific, Pittsburgh, PA) and grown overnight at 35°C in an 8% CO~2~incubator. One microliter loop of culture was quadrant streaked on blood neomycin plates (Fisher Scientific, Pittsburgh, PA) in order to obtain isolated colonies. Single colonies were then inoculated in 5 ml of LB broth and grown overnight under the same conditions stated above. Cultures (700 μl) were placed in 1.5 ml cryovial tubes with 300 μl of 50% glycerol to make glycerol stocks. Samples were then flash frozen with liquid nitrogen and stored at -80°C. Glycerol stocks were streaked overnight onto blood neomycin plates and colonies with a clear zone of hemolysis were selected for PCR amplification.

Serotyping of GBS Isolates
--------------------------

Classification of GBS samples was done by PCR-based restriction fragment length polymorphism (RFLP) capsular typing to distinguish among nine of the ten known GBS serotypes (Ia, Ib, II-IX). We used PCR primers and conditions published by Manning *et al*(cpsG-F97, cpsL-R200, cpsR8-F40) \[[@B9]\]. These primers were used to amplify DNA fragments using Pure Taq Ready-to-Go PCR Beads (GE Healthcare, Pittsburgh, PA) followed by digestion with DdeI (New England Biolabs, Ipswich, MA) to generate restriction fragments. Digested amplicons were separated on 1.8% agarose gels and analyzed using a Typhoon 9410 variable mode imager (GE Healthcare, Piscataway, NJ). Serotype classification was determined by comparison of the molecular weight banding pattern of the resulting restriction fragment length polymorphisms (RFLPs) with published DNA fragment sizes of the GBS *cps*gene cluster \[[@B9]\].

Serotyping by multiplex polymerase chain reaction
-------------------------------------------------

GBS-specific primers (DLTS) were used to identify those isolates that were nontypeable (NT) by RFLP analysis of the *cps*gene cluster. Multiplex PCR confirmed serotype classification and serotyped GBS isolates that yielded ambiguous results by the RFLP analysis of the *cps*gene cluster. Multiplex PCR was performed on single colonies using Pure Taq PCR Ready-to-Go PCR beads using the cps primers and PCR conditions published by Poyart *et al*\[[@B10]\]. Isolates classified as NT by both methods were serotyped using the primers and methods detailed in Imperi *et al*\[[@B7]\].

Statistical analysis, systematic review, and multiple comparisons analysis
--------------------------------------------------------------------------

An *a priori*power analysis indicated that a minimum of 400 patients should be enrolled in the study, assuming a 20% rate of colonization with 5% error to determine prevalence with a precision (α) of 5% \[[@B11]\]. Based on this estimation, a total of 1129 patients were screened, of which 207 (18.3%) were determined to be GBS positive. To compare the Madigan cohort to the global serotype distributions, a systematic review was conducted of 426 primary literature references evaluating serotype distribution in discrete geographical regions. These studies were identified in a Pub Med keyword search for references reporting population serotyping data for GBS (through February 2010). Studies were excluded if GBS was obtained from normally sterile sites (i.e., blood, synovial fluid, etc.). Studies reporting serodistribution in neonates were likewise excluded. Of the papers surveying predominantly colonized women, we excluded studies predating the emergence of serotype V in the general population. Where raw numbers were available, we confirmed the investigator-reported serotype percentages by our own independent calculations. In two instances, the frequencies we calculated did not match the percentages reported in the article due to obvious typographical errors. We relied solely on data in article abstracts where the full text articles were not written in the English language or if the full text article could not be procured. Meta-data were compiled by calculating proportions of serotype distribution among all GBS-positive diagnoses segregated by geographical region (Table [1](#T1){ref-type="table"}). Studies included in the global statistical analysis are presented in systematic review in Table [2](#T2){ref-type="table"} (United States and Canada) \[[@B12]-[@B26]\] and Table [3](#T3){ref-type="table"} (global data) \[[@B11],[@B27]-[@B64]\]. The proportional z-test was used to determine significance between serotype rates of the Madigan cohort and other regions. The statistical significance level was stringently set by the Bonferroni correction method to be p \< 0.005.

###### 

Multiple comparisons analysis comparing the Madigan cohort with global GBS serotype distributions.

                   Serotype Distribution (%)                                                                                                           
  --------- ------ --------------------------- ----------- ----------- ----------- ---------- ----------- ---------- ---------- ---------- ----------- ----------------
  Madigan   207    59                          25          25          56          4          35          2          0          0          1           **\#patients**
                   **28.50**                   **12.08**   **12.08**   **27.05**   **1.93**   **16.91**   **0.97**   **0.00**   **0.00**   **0.48**    **%**
                                                                                                                                                       
  Canada    353    77                          35          40          66          5          78                                1          49          **\#patients**
                   **21.81**                   **9.92**    **11.33**   **18.70**   **1.42**   **22.10**   **0.00**   **0.00**   **0.28**   **13.88**   **%**
                   0.104                       0.512       0.906       0.027       0.918      0.171                                        0.001       **p-value**
                                                                                                                                                       
  US        7609   2039                        618         826         1887        73         1139        26         3          17         869         **\#patients**
                   **26.80**                   **8.12**    **10.86**   **24.80**   **0.96**   **14.97**   **0.34**   **0.04**   **0.22**   **11.42**   **%**
                   0.642                       0.055       0.658       0.511       0.299      0.501       0.364                            0.001       **p-value**
                                                                                                                                                       
  Europe    2662   485                         329         384         747         98         396         16         16         15         131         **\#patients**
                   **18.22**                   **12.36**   **14.43**   **28.06**   **3.68**   **14.88**   **0.60**   **0.60**   **0.56**   **4.92**    **%**
                   0.001                       0.93        0.407       0.817       0.265      0.492       0.847                            0.006       **p-value**
                                                                                                                                                       
  ME, EEu   566    78                          24          76          82          17         79          10         7          0          41          **\#patients**
                   **13.78**                   **4.24**    **13.43**   **14.49**   **3.00**   **13.96**   **1.77**   **1.24**   **0.00**   **7.24**    **%**
                   0.001                       0.001       0.709       0.001       0.575      0.363       0.64                             0.001       **p-value**
                                                                                                                                                       
  Asia      1521   171                         214         132         446         25         266         81         22         48         85          **\#patients**
                   **11.24**                   **14.07**   **8.68**    **29.32**   **1.64**   **17.49**   **5.33**   **1.45**   **3.16**   **5.59**    **%**
                   0.001                       0.502       0.142       0.553       0.987      0.913       0.01                             0.003       **p-value**
                                                                                                                                                       
  Africa    260    37                          12          22          89          10         82          0          0          0          7           **\#patients**
                   **14.23**                   **4.62**    **8.46**    **34.23**   **3.85**   **31.54**   **0.00**   **0.00**   **0.00**   **2.69**    **%**
                   0.001                       0.005       0.256       0.118       0.349      0.001                                        0.142       **p-value**
                                                                                                                                                       
  S. Am     113    23                          12          28          13          2          6                                            10          **\#patients**
                   **20.35**                   **10.62**   **24.78**   **11.50**   **1.77**   **5.31**    **0.00**   **0.00**   **0.00**   **8.85**    **%**
                   0.144                       0.836       0.006       0.002       0.749      0.005                                        0.001       **p-value**
                                                                                                                                                       
  Mexico    492    277                                     112         88                                                                  16          **\#patients**
                   **56.30**                   **0.00**    **22.76**   **17.89**   **0.00**   **0.00**    **0.00**   **0.00**   **0.00**   **3.25**    **%**
                   0.001                                   0.002       0.009                                                               0.057       **p-value**
                                                                                                                                                       
  Aus, NZ   125    25                          24          5           26          4          37          0                     0          2           **\#patients**
                   **20.00**                   **19.20**   **4.00**    **20.80**   **3.20**   **29.60**   **0.00**   **0.00**   **0.00**   **1.60**    **%**
                   0.111                       0.107       0.022       0.251       0.728      0.01                                         0.655       **p-value**

NOTE. Bonferroni correction alpha = 0.05/p = 0.005 (two-sided); statistical significance \< 0.005 relative to Madigan cohort

Madigan, Madigan Healthcare System; ME, Middle East; EEu, Eastern Europe; S.Am, South America; Aus, Australia; NZ,New Zealand

###### 

United States and Canada GBS Seroprevalences Relative to Madigan Distribution

                                                                                                              Prevalence by Serotype (%)                                                                               
  ------------------------- ------------ -------------------------- --------- ---------- ---------- --------- ---------------------------- -------- -------- -------- ------- -------- ------- ------- ------- ------- -------------------
  **WA (Madigan)**          **2010**     **Women**                  **PCR**   **1129**   **18.3**   **207**   **29**                       **12**   **12**   **27**   **2**   **17**   **1**   **0**   **0**   **1**   **this study**
  Canada Alberta            1998-2000    Gravidas                   OID       NA         NA         118       20                           9        9        15       0       28                       0       20      \[[@B15]\]
  Canada Calgary            1998-2000    Gravidas                   OID       1207       19.5       235       23                           11       13       21       2       19                       0.4     11      \[[@B15]\]
  MA Boston                 1999         \>94% Women                ELISA     NA         NA         114       25                           5        10       24       0       32       0               0.9     4       \[[@B23]\]
  MA Boston                 1962-1963    \>90% Women                ELISA     NA         NA         149       46                           14       11       22               0                        0       7       \[[@B23]\]
  MI                        1997-2000    Adults                     DB        NA         NA         338       21                           12       13       13       1       22       2       0       0.3     12      \[[@B20]\]
  MI                        1999-2000    Gravidas                   LCP       NA         NA         117       18                           11       11       19       1       20       2                       17      \[[@B19]\]
  MI^c^                     1999-2000    92% Adults                 DB        NA         NA         306       23                           12       14       11       3       30       3       0.7     2       1       \[[@B12]\]
  MN                        1974- 1975   3rd Trimester Gravidas     CP        802        5.6        45        26                           13       24       24                                                13      \[[@B17]\]
  MN                        1993-1999    Adults                     NA        NA         NA         138       21                           14       16       5        0.7     35                               9       \[[@B24]\]
  OH                        2001-2002    Gravidas, urine cultures   LCP       65         2.8        2318      23                           4        4        32       2       6                                30      \[[@B21]\]
  OH                        2003                                              NA         NA         349       18                           9        11       17               27                                       \[[@B14]\]
  PA Pittsburgh             1993-2002    non pregnant women         IP        NA         NA         2660      34                           11       13       25       0.4     15       0.3     0       0.3     2       \[[@B16]\]
  PA Pittsburgh             1998-2000    non pregnant women         DB        NA         NA         177^b^    31                           9        15       28       0.6     14                               3       \[[@B22],[@B26]\]
  TX                        1994-1995    Gravidas                   AS        546        28         153       24                           9        26       24       0       12                               4       \[[@B18]\]
  WA, TX Seattle; Houston   1992-1995    Gravidas                   ID        3307       26         856       26                           8        18       21       0       21       0.2                     1       \[[@B13]\]
  WV                        1999         Females                    LA        NA         NA         84        19                           13       9        15       4       15                               9       \[[@B25]\]

a\--Ic from earlier studies is grouped with Ia

b\--of 270 GBS+ patients, 177 were serotyped

c\--mixed population: 267 adults - Michigan, 24 neonates - Houston, TX

Madigan-Madigan Healthcare System, Tacoma, WA

LCP-Lancefield capillary precipitin

OID-Ouchterlony immunodiffusion

DBC-dotblot capsular typing

ID-immunodiffusion with rabbit antisera

IP-immunoprecipitation in agarose

LA-latex agglutination with serotype specific sera

NA-not available

AS-antisera

###### 

Global GBS Serotype Distribution in Reproductive-Age Adults Relative to Madigan Healthcare System.

                                                                                                                                                                                Prevalence by Serotype (%)                                                                                    
  -------------------------------------------------------------------------------------------------------- ------------- ------------ --------- ---------- ---------- --------- ---------------------------- -------- -------- -------- ------- -------- ------- ------- ------- ------------ ----------------
  **Madigan, USA**                                                                                         **2010**      **Women**    **PCR**   **1129**   **18.3**   **207**   **29**                       **12**   **12**   **27**   **2**   **17**   **1**   **0**   **0**   **0.5**      **this study**
                                                                                                                                                                                                                                                                                              
  **Europe**                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                              
  Czech R                                                                                                  2001-2002     Gravidas     IP        586        29.4       172       22                           \~10     \~13     33       0       14       \~3                     1.8          \[[@B46]\]
  France^T^                                                                                                2001          Gravidas     PCR       39         8          500       26                           8        8        41               18                                            \[[@B60]\]
  *Germany*                                                                                                1997-1999     Gravidas     EA        NA         NA         146       18                           8        15       29       3       13                               14           \[[@B63]\]
  *Germany*                                                                                                2001-2003     Gravidas     OID       460        23         104(75)   17                           15       21       28       3       16       0       0       0       0            \[[@B30]\]
  *Greece*                                                                                                 2000-2001     Gravidas     LA        1014       6.6        67        19                           12       27       22       3       9        3       3       2                    \[[@B58]\]
  Ireland                                                                                                  1998 pub      Women        NA        504        25.6       129       30                                    17       30       1       9                                             \[[@B40]\]
  Ireland                                                                                                  1999-2001     Gravidas     IP        NA         NA         20        35                           5        0        30       0       20       0       0       0       5            \[[@B11]\]
  Ireland^D^                                                                                               2003 pub      Gravida^c^   NA        NA         NA         159       20                           19       11       30       2       15                               4            \[[@B32]\]
  *Italy*^*P*^                                                                                             1993-1995     Gravidas     OID       2300       11.3       260       16                           27       22       22       3       5        0       0       5                    \[[@B52]\]
  *Italy*^*T*^                                                                                             2005-2006     Gravidas     LA        400        18         73        21                           7        6        33       8       26                                            \[[@B51]\]
  *Netherl*                                                                                                1999-2004     Gravidas     LA        NA         NA         92        26                           7        13       22       8       15       8                                    \[[@B61]\]
  *Portugal*^*L*^                                                                                          2002-2004     Gravidas     LA        NA         NA         269       16                           5        17       22       2       22       0       2       0       14           \[[@B44]\]
  Sweden                                                                                                   2005          Women        LA,PCR    1579       25.4       356       11                           13       16       24       15      19       0.5     1       0       1            \[[@B38]\]
  Sweden                                                                                                   1995-1996     Gravidas     LA, IP    NA         NA         114       13                           13       11       32       3       22                               6            \[[@B29]\]
  *U.K.*                                                                                                   2001-2003     Gravidas     LA        748        21.3       159       26                           16       9        26               19                               2            \[[@B39]\]
                                                                                                                                                                                                                                                                                              
  **Eastern Europe/Middle East**                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                              
  *Kuwait*                                                                                                 2004 pub      Gravidas     AS        847        14.6       124       13                           2        8        24       1       22       8       6       0       17           \[[@B27]\]
  Iran                                                                                                     2003          Gravidas     NA        110        9.1        1197                                                                                                                    \[[@B49]\]
  *Israel*                                                                                                 2000          Gravidas     AS        681        12.3       84        18                           11       27       20               14                                            \[[@B43]\]
  Lebanon                                                                                                  2006          Gravidas               775        17.7       137       15                           7        11       16       1       23                               29           \[[@B53]\]
  *Turkey*                                                                                                 2000 2001     Gravidas     LA        500        9.2        54        26                           4        29       19       2       0                                20           \[[@B34]\]
  UAE                                                                                                      1998-1999     Gravidas     ID        563        10.1       57        21                                    4        18       26      12                               16           \[[@B28]\]
                                                                                                                                                                                                                                                                                              
  **Asia**                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                              
  India^D^                                                                                                 1980s         Women        NA        NA         NA         110                                    20       40       30                                                10           \[[@B64]\]
  India^V^                                                                                                 1980s         Women        NA        NA         NA         79        20                           41       53       6                                                              \[[@B64]\]
  *Japan*                                                                                                  1999-2000     Gravidas     ELISA     48         8.2        583       8                            13       8        10       0       6        19      0       27      8            \[[@B45]\]
  *Japan*                                                                                                  1992-2001     Gravidas     IS                                        9                            6        2        10               9        27              32      6            \[[@B56]\]
  *Japan*                                                                                                  1992-1994     Gravidas     E, OID    441        16         71        7                            8        0        11       0       4        25      0       36      10           \[[@B41]\]
  *Korea*                                                                                                  2006-2008     Gravidas     LA        2624       8          352       12                           10                44               20                               2            \[[@B42]\]
  *Korea*                                                                                                  1990-2000     Gravidas     LA        NA         NA         446       10                           22       2        37       1       21       4       1       1       1            \[[@B59]\]
  Malaysia                                                                                                 2008          Gravidas     LA        NA         NA         200       12                           2        6        12       10      19       17      5       2       17           \[[@B31]\]
  Myanmar^Y^                                                                                               1999-2001     Gravidas     CP        226        7.1        14        14                           0        36       0        0       36       0       0       0       14           \[[@B11]\]
  Taiwan                                                                                                   2000-2005     Gravidas     LA        NA         NA         58        22                           9        3        33       0       26       3                                    \[[@B61]\]
  Phillip^M^                                                                                               1999-2001     Gravidas     CP        200        7.5        15        7                            7        27       33       0       13       0       0       7       7            \[[@B11]\]
  Thailand^BK^                                                                                             1999-2001     Gravidas     CP        400                   52        17                           2        13       17       0       27       0       15      0       8            \[[@B11]\]
                                                                                                                                                                                                                                                                                              
  **Africa**                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                              
  Gambia                                                                                                   1998          Gravidas     AbTyp     136        19.9       27        19                           4        26       7        4       37                               4            \[[@B55]\]
  Nigeria                                                                                                  Early 1980s   Women        NA        NA         NA         89                                     12       6        62                                                20           \[[@B64]\]
  Zimbabwe^H^                                                                                              1999-2001     Gravidas     CP        210        11.9       21        10                           14       5        24       0       43       0       0       0       5            \[[@B11]\]
  Zimbabwe                                                                                                 2000 end      Gravidas     AbTyp     206        31.6       65        11                           3        1        42       3       37                               2            \[[@B48]\]
  Zimbabwe                                                                                                 2002 end      Gravidas     AbTyp                           117       15                           5        4        45       5       24                               2            \[[@B47]\]
                                                                                                                                                                                                                                                                                              
  **South/Central America and Mexico**                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                              
  Argentina                                                                                                NA            Gravidas     LA        531        3.2        17                                                                                                                      \[[@B57]\]
  Brazil                                                                                                   2003-2004     Gravidas     AS        316        14.6       46        17                           24       20       4        7       9                                17           \[[@B54]\]
  Mexico                                                                                                   2000          Gravidas     LA        946        13         123       59                           30       6                                                  6       \[[@B62]\]   
  Mexico                                                                                                   2000-2001     Women        LA                              25        68                           4        28                                                         \[[@B62]\]   
  Mexico                                                                                                   1999-2001     Gravidas     LA        691        14         97        62                           26       13                                                         \[[@B36]\]   
  Mexico                                                                                                   1988-1998     Gravidas     LA                              169       44                                    20       30                                                5            \[[@B50]\]
  Mexico                                                                                                                 Gravidas                                     78        68                           19       13                                                         \[[@B36]\]   
                                                                                                                                                                                                                                                                                              
  **Australia/New Zealand**                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                              
  N. Zea                                                                                                   1998-1999     Gravidas     ID; PCR   240        52         22        21                           20       6        29               20       2               2                    \[[@B37]\]
  *Australia*                                                                                              1991-1992     Adults^b^    LA                              103       19                           19       4        19       4       32                               1.9          \[[@B33]\]
  ***Italicized countries host US military bases (source: Military.com at***<http://www.military.com/> )                                                                                                                                                                                      

a\--Ic from earlier studies is grouped with Ia

b\--genital/urine data only are compiled

c\--70% Gravidas

Madigan\--Madigan Healthcare System, Tacoma, WA

pub\--study publication date; interval not given

LCP-Lancefield capillary precipitin

AbTyp\--Antibody typing

OID-Ouchterlony immunodiffusion

DBC-dotblot capsular typing

ID-immunodiffusion with rabbit antisera

IP-immunoprecipitation in agarose

LA-latex agglutination with serotype specific sera

E\--ELISA

NA-not available

EA-enzyme extraction

CP-capillary precipitation

Czech R\--Czech Republic

France^T^\--France (Tours)

Ireland^D^\--Ireland (Dublin) Italy^P^\--Italy (Perugia)

Italy^T^\--Italy (Turin)

Netherl\--Netherlands

Portugal^L^\--Portugal (Lisbon)

UAE\--United Arab Emirates

India^D^\--India (Delhi)

India^V^\--India (Vellore)

Myanmar^Y^\--Myanmar (Yangon)

Philippines^M^\--Philippines (Manila)

Thailand^BK^\-- (Bankok, Kohn Kaen)

Zimbabwe^H^\--Zimbabwe (Harare)

NZ\--New Zealand

Results
=======

Four isolates were classified as NT by PCR amplification and DdeI restriction endonuclease digest alone. These isolates were confirmed to be GBS antigen B by GBS-specific primers dlts-F and dlts-R. Isolates were further screened by a multiplex approach to verify CPS serotype \[[@B10]\]. The single isolate not typeable by either method was further screened by GBS IX-specific primers \[[@B7]\], but results were negative. The serotype distribution results of the multi-tiered typing strategies are presented in Figure [1](#F1){ref-type="fig"}. Our results show that serotypes Ia, III, and V were the most abundant of the screened GBS isolates (28.5%, 27.1%, and 16.9%, respectively), followed by the less prevalent serotypes Ib, II, IV, and VI (12.1%, 12.1%, 1.9%, and 1.0%, respectively). GBS serotypes VII, VIII, and IX were not detected in our population group and one isolate was NT.

![**Prevalence of GBS serotypes at Madigan Healthcare System July 2009 - December 2009**. Serotype was determined for GBS isolates collected from vaginal/rectal swabs from women of indeterminate gravidity at Madigan Healthcare System (Joint Base Lewis-McChord, Washington, USA). Percentages refer to serotype frequency in 207 total isolates screened. Total numbers of patients testing positive for each isolate are listed in parentheses. NT, non-typeable.](1471-2334-10-336-1){#F1}

A systematic review of the literature compared Madigan seroprevalences with those reported within the rest of the United States (Table [2](#T2){ref-type="table"}) and internationally (Table [3](#T3){ref-type="table"}). Global proportions were combined by geographical region into a composite multiple comparisons analysis to compare Madigan serotype distributions with the rest of the world (Table [1](#T1){ref-type="table"}). Because most studies conducted in Mexico did not segregate serotype I into Ia and Ib, these studies were included in the systematic review (Table [3](#T3){ref-type="table"}) but not in the final analysis (Table [1](#T1){ref-type="table"}).

Discussion
==========

To determine the serotype of our Madigan population GBS isolates, we used a two-tiered PCR-based approach to identify type-specific capsular polysaccharides (CPS), epidemiologic markers used to classify serotypes according to prevalence for colonization and disease. The most common mechanism for identifying serotypes is serotype-specific latex agglutination analysis, but this method is prohibitively expensive when used on large patient populations \[[@B65]\]. Further, these tests have lower accuracy, and result in numerous NT isolates (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). In contrast, the polymerase chain reaction (PCR) based capsular typing techniques used in this study (i.e., RFLP analysis and multiplex PCR) are reproducible, specific, and easy to perform with fewer NT isolates reported \[[@B9],[@B10]\]. We chose a two-tiered PCR approach, first using a restriction enzyme digest fingerprinting strategy followed by multiplex PCR for serotypes classified as NT by the RFLP methods \[[@B9],[@B10]\]. There was 100% concordance between the two methods used to screen isolates, confirming accuracy of the classification scheme used in determining seroprevalences at Madigan.

The percentage of NT isolates reported in our study is significantly lower than that reported in international civilian GBS serotype surveillance studies using primarily the serotype-specific latex agglutination method (2-13%; Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, and [3](#T3){ref-type="table"}) \[[@B65]-[@B67]\]. The 0.5% (n = 1 NT isolate) could result from an uncharacterized capsule \[[@B68]\], mutation in the capsular genes \[[@B69]\], or reversible nonencapsular phase variations \[[@B70]\]. Thus, the PCR-based method has proven an effective screening strategy for rapid and effective screening in a military population, and is anticipated to improve typing accuracy in larger cohorts as these methods become more widespread in surveillance studies.

To our knowledge, this is the first GBS serotype surveillance study targeting a population comprised solely of military beneficiaries. The primary mission of infectious disease research initiatives at military operated facilities is to identify and reduce the impact of infectious diseases affecting military populations. In accordance with this objective, this study reports a strikingly similar GBS distribution profile at Madigan relative to United States and Canadian studies (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). In comparing seroprevalences in the US with the Madigan cohort, our data suggest that seroprevalences have remained relatively stable in the United States over the past two decades since the emergence of serotype V in the mid-1990s (Table [2](#T2){ref-type="table"}). Subtle regional differences in demographic makeup have been reported to affect GBS serodistribution within the same country \[[@B31]\]. Serotypic shifts have been reported in regional distributions in Korean study populations, for example, with a shift in prevalence of serotypes III and V depending on study site \[[@B42]\]. Regional data in early onset invasive GBS strains in neonates in the US indicate that GBS serotypes vary significantly according to study site, with more cases of serotype V reported in New Jersey and New York populations than in Florida, Texas, and Alabama \[[@B71]\]. However, combining study populations by geographical location led to a striking similarity between Madigan and the civilian sector in North America (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). It is currently unknown how rapidly seroconversion occurs in the general population. Our data plausibly reflect a stabilization of seroprevalence in the US over the past 15 years. However, very recent data indicate that serotype IV may be increasing in prevalence in the United States (8.4% of the 1160 patients enrolled from 2004 - 2008 in a multi-site United States study) \[[@B72]\].

Relative to global serodistribution studies, our statistical analysis indicates that North American populations have a higher representation of serotype Ia relative to other geographical locations (Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}). Since the emergence of serotype V in the general population, distributions of serotype proportion have shifted to accommodate the rise in serotype V prevalence in recent years in pregnant patients and neonates with invasive GBS disease \[[@B73]\]. Our global surveillance analysis suggests that Africa and South America have significantly greater serotype V representation relative to North American populations (Table [1](#T1){ref-type="table"}).

The rate of GBS colonization rate at Madigan is comparable to the civilian-sector United States and Canada but differs from colonization rate reported in global surveillance studies (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Data from the Emerging Pathogens Network places the overall GBS colonization incidence among U.S. women at approximately 10-30% \[[@B1],[@B4]\]. At Madigan, GBS colonization rate was 18.3% during the study interval. East Asian countries report incidences as low as 0.3-5.9% \[[@B42]\], while African countries such as Zimbabwe report greater than 60% colonization in pregnant patients (Table [3](#T3){ref-type="table"}) \[[@B74]\]. Ethnicity could account for some of these differences. African Americans and Hispanic Americans, for example, are GBS-colonized at higher rates than Caucasians \[[@B4],[@B75]\]. Further, African American heritage is a recognized risk factor for early onset sepsis in neonates born to colonized mothers \[[@B1]\]. Finally, the mode of specimen collection (i.e., vaginal, rectal, or vaginal/rectal) has been reported to vary significantly depending on geographical location \[[@B1]\]. We recognize that mode of collection may bias estimates of global colonization and/or serodistribution.

Besides ethnicity and vertical transmission between colonized mother and neonate, colonization has also been associated with sexual contact and diet \[[@B22],[@B76]-[@B79]\]. All modes are relevant to the Madigan population of highly mobile military beneficiaries and could account for the differences in GBS colonization rate observed between the Madigan cohort and the global studies.

Our systematic review and statistical comparison of the Madigan cohort with global epidemiological studies indicates variability in the geographical distribution of GBS serotypes (Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}). Studies with populations originating in Europe, Asia, Africa, Australia, and North and South America have reported significant differences in prevalence and emergence of novel serotypes over time (Table [3](#T3){ref-type="table"}). When comparing Madigan seroprevalences with the global distributions, the Madigan cohort most closely resembles studies conducted in the continental United States and Canada (Table [2](#T2){ref-type="table"}) \[[@B23]\].

Analysis of Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"} prompts the following conclusions regarding the seroprevalence of GBS in the Madigan cohort relative to international cohorts: (1) Ia is higher in North America relative to the rest of the world; (2) Ia and Ib are considerably higher in Mexico and South America; (3) III is lower in the Middle East and Eastern Europe than North America but higher in Africa and Australia/New Zealand; (4) IV is comparable across continents; (5) V is higher in Africa but much lower in Australia/New Zealand than North American populations; and (6) VI/VIII are most prevalent in Japan while (7) VII is least represented across the globe with occasional isolates reported in the Middle East/Eastern Europe and Asia. Limited population seroprevalance data are available for serotype IX given its very recent emergence in the general population \[[@B5],[@B7]\]. Given that serotypes III and V (and to a lesser extent Ia) are most commonly associated with late onset neonatal illness, trends in locations such as Korea, Australia/New Zealand, and African countries with proportionally higher III seroprevalences underscore the need for continuing surveillance. An important caveat when interpreting the meta-data is the high NT rate reported in some studies (11.4-13.88%). The molecular methods more accurately assess serotype, potentially biasing the reporting of the serodistribution in the global comparative analyses.

Given the limited data available on GBS transmission \[[@B22],[@B76]-[@B79]\], surveillance studies are warranted in military hospitals located in regions reporting unique seroprevalences. Serotypes typical of discrete geographical regions (i.e., VI and VIII) were less prevalent in our Madigan population (Table [1](#T1){ref-type="table"}). Serotypes VIII and VI are most prevalent in Japan \[[@B41]\], a country which hosts numerous U.S. military bases and associated military hospitals. However, we report no incidences of VIII and only a small percentage of VI serotypes in our Madigan population. Similarly, neonatal GBS type IV disease has been reported as more prevalent in countries such as the United Arab Emirates than the United States \[[@B28]\]. Interestingly, our serodistribution data indicate that IV is the most stable serotype across all countries in the world, with no statistically significant differences reported (Table [1](#T1){ref-type="table"}). Surveillance studies of seroconversion in female military operatives are warranted in military medical facilities located in Japan and the Middle East.

The implementation of CDC guidelines for anovaginal swab screening at 35-37 weeks gestation and subsequent intrapartum chemoprophylaxis in culture-positive individuals has reduced the incidence of GBS disease by 70% \[[@B1],[@B8],[@B80]\]. However, more than 25% of women now receive intrapartum antibiotics \[[@B81]\], raising public health concerns over the possibility of increasing antibiotic resistance of other common pathogens affecting neonatal health \[[@B2]\]. Further, although GBS readily succumbs to penicillin regimens, resistance is increasing in antibiotic alternatives such as clindamycin and erythromycin in women with penicillin allergy \[[@B82],[@B83]\]. One strategy currently underway to combat this problem is the development of multivalent vaccines. Although vaccination efficacy and implementation feasibility remain controversial, understanding serotype distribution as a function of population is recognized as a critical component of vaccine development \[[@B6],[@B84]\].

Conclusions
===========

In conclusion, the two-tiered molecular approach to GBS serotype analysis proved a viable strategy for assessing GBS serodistribution in the Madigan cohort, with fewer NT isolates than other methods employed in large population serodistribution studies. The ethnic diversity and geographical mobility of the United States military classify the military as a unique epidemiologic unit relative to US regional and global surveillance populations surveyed in our systematic review. However, the serodistributions reported in our study are remarkably comparable to those reported in civilian sector hospitals in the United States and Canada. Significant discrepancies exist between Madigan distributions and global epidemiology. Investigating seroprevalence in US military medical facilities abroad is necessary to determine whether military-specific populations will require specialized risk analysis for emerging GBS pathogens when alternatives to chemoprophylaxis come into clinical practice.
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